Beta Bionics (BBNX) Competitors $14.14 +0.20 (+1.43%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock BBNX vs. LIVN, WRBY, NVCR, LMAT, ENOV, EYE, CNMD, AORT, TNDM, and CDREShould you be buying Beta Bionics stock or one of its competitors? The main competitors of Beta Bionics include LivaNova (LIVN), Warby Parker (WRBY), NovoCure (NVCR), LeMaitre Vascular (LMAT), Enovis (ENOV), National Vision (EYE), CONMED (CNMD), Artivion (AORT), Tandem Diabetes Care (TNDM), and Cadre (CDRE). These companies are all part of the "medical equipment" industry. Beta Bionics vs. Its Competitors LivaNova Warby Parker NovoCure LeMaitre Vascular Enovis National Vision CONMED Artivion Tandem Diabetes Care Cadre LivaNova (NASDAQ:LIVN) and Beta Bionics (NASDAQ:BBNX) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, risk, media sentiment, profitability and institutional ownership. Does the media favor LIVN or BBNX? In the previous week, Beta Bionics had 5 more articles in the media than LivaNova. MarketBeat recorded 5 mentions for Beta Bionics and 0 mentions for LivaNova. LivaNova's average media sentiment score of 0.94 beat Beta Bionics' score of 0.70 indicating that LivaNova is being referred to more favorably in the media. Company Overall Sentiment LivaNova Positive Beta Bionics Positive Do analysts recommend LIVN or BBNX? LivaNova presently has a consensus target price of $59.29, indicating a potential upside of 28.66%. Beta Bionics has a consensus target price of $23.44, indicating a potential upside of 65.80%. Given Beta Bionics' higher probable upside, analysts plainly believe Beta Bionics is more favorable than LivaNova.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LivaNova 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.00Beta Bionics 0 Sell rating(s) 4 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.75 Do institutionals & insiders believe in LIVN or BBNX? 97.6% of LivaNova shares are owned by institutional investors. 0.3% of LivaNova shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Is LIVN or BBNX more profitable? Beta Bionics has a net margin of 0.00% compared to LivaNova's net margin of -17.41%. LivaNova's return on equity of 13.67% beat Beta Bionics' return on equity.Company Net Margins Return on Equity Return on Assets LivaNova-17.41% 13.67% 6.68% Beta Bionics N/A N/A N/A Which has better earnings and valuation, LIVN or BBNX? LivaNova has higher revenue and earnings than Beta Bionics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLivaNova$1.28B1.97$63.23M-$4.09-11.27Beta Bionics$65.12M9.42-$54.76MN/AN/A SummaryLivaNova beats Beta Bionics on 8 of the 13 factors compared between the two stocks. Get Beta Bionics News Delivered to You Automatically Sign up to receive the latest news and ratings for BBNX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BBNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BBNX vs. The Competition Export to ExcelMetricBeta BionicsMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$613.11M$6.86B$5.49B$8.94BDividend YieldN/A1.04%5.38%4.12%P/E RatioN/A26.5426.2119.90Price / Sales9.4296.06415.38165.30Price / CashN/A21.0536.4957.06Price / Book-2.474.748.055.38Net Income-$54.76M$173.18M$3.15B$248.50M7 Day Performance-4.27%1.45%1.85%2.97%1 Month Performance-24.34%0.27%4.81%6.02%1 Year PerformanceN/A29.02%34.86%20.39% Beta Bionics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BBNXBeta BionicsN/A$14.14+1.4%$23.44+65.8%N/A$613.11M$65.12M0.00294News CoverageLIVNLivaNova2.8845 of 5 stars$45.80-0.2%$59.29+29.4%-16.0%$2.50B$1.25B-11.202,900WRBYWarby Parker2.1065 of 5 stars$21.51-1.3%$22.88+6.4%+37.4%$2.28B$771.32M-179.233,780Positive NewsNVCRNovoCure3.7922 of 5 stars$17.10-1.3%$32.83+92.0%+3.1%$1.93B$605.22M-11.321,488Positive NewsLMATLeMaitre Vascular2.5574 of 5 stars$82.40-2.5%$97.83+18.7%+3.9%$1.91B$219.86M41.62490Positive NewsENOVEnovis3.5205 of 5 stars$32.28+0.5%$58.00+79.7%-25.6%$1.84B$2.11B-2.317,367News CoveragePositive NewsEYENational Vision2.5917 of 5 stars$23.06+0.0%$18.67-19.1%+91.0%$1.82B$1.82B-69.8813,411Positive NewsHigh Trading VolumeCNMDCONMED4.6147 of 5 stars$52.36-0.1%$62.20+18.8%-19.3%$1.62B$1.31B13.783,900AORTArtivion2.612 of 5 stars$30.58-0.1%$32.00+4.7%+20.7%$1.31B$388.54M-61.151,600Positive NewsTNDMTandem Diabetes Care4.2968 of 5 stars$19.11-1.6%$33.43+74.9%-56.3%$1.29B$940.20M-6.872,650Positive NewsCDRECadre3.6666 of 5 stars$32.23+1.9%$37.50+16.4%-3.9%$1.29B$567.56M33.922,284 Related Companies and Tools Related Companies LivaNova Competitors Warby Parker Competitors NovoCure Competitors LeMaitre Vascular Competitors Enovis Competitors National Vision Competitors CONMED Competitors Artivion Competitors Tandem Diabetes Care Competitors Cadre Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BBNX) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored379 passengers walked away from thisElon Musk just wrote a $51 million check to back this material’s next phase… Because it’s not just saving l...True Market Insiders | SponsoredIsrael-Iran WAR Could Destroy Trump's PresidencyThe missiles are already flying. Israel and Iran are now in direct military conflict — and this couldn't ha...American Alternative | SponsoredSomething very strange is happening...What a "Mar-a-Lago Accord" could mean for the U.S. dollar While protests dominate the news... hardly anyone...Stansberry Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Beta Bionics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Beta Bionics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
